Philippe Jamme

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients

Clotilde Descarpentries, Frédéric Leprêtre, Fabienne Escande et al. · Journal of Thoracic Oncology · 2018 · 42 citations · Full text

Medicine, Genetics, Oncology +13

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study

Simon Baldacci, Martin Figeac, Martine Antoine et al. · Journal of Thoracic Oncology · 2019 · 27 citations · Full text

Medicine, Genetics, Molecular Genetics +9

<scp>MET</scp> exon 14 skipping mutation is a hepatocyte growth factor (<scp>HGF</scp>)‐dependent oncogenic driver <i>in vitro</i> and in humanised <i>HGF</i> knock‐in mice

Marie Fernandes, Brynna Hoggard, Philippe Jamme et al. · Molecular Oncology · 2023 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

Marie Véron, Sylvie Chevret, Jean‐Jacques Grob et al. · European Journal of Cancer · 2022 · 22 citations

Life Sciences, Immunology, Oncology +15

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma

Anthony Turpin, C. Descarpentries, V. Grégoire et al. · The Oncologist · 2022 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17